Helixmith Past Earnings Performance
Past criteria checks 0/6
Helixmith has been growing earnings at an average annual rate of 10.4%, while the Biotechs industry saw earnings growing at 12.4% annually. Revenues have been declining at an average rate of 2.5% per year.
Key information
10.4%
Earnings growth rate
17.5%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -2.5% |
| Return on equity | -39.4% |
| Net Margin | -1,652.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Helixmith makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3,548 | -58,628 | 15,101 | 13,964 |
| 31 Dec 23 | 4,202 | -64,088 | 18,844 | 17,145 |
| 30 Sep 23 | 4,415 | -38,214 | 18,471 | 24,101 |
| 30 Jun 23 | 4,092 | -41,015 | 21,358 | 26,438 |
| 31 Mar 23 | 3,497 | -42,099 | 22,910 | 28,389 |
| 31 Dec 22 | 2,800 | -43,538 | 23,299 | 28,101 |
| 30 Sep 22 | 2,892 | -55,434 | 24,994 | 30,804 |
| 30 Jun 22 | 2,774 | -48,650 | 23,471 | 28,588 |
| 31 Mar 22 | 2,701 | -61,863 | 23,521 | 25,752 |
| 31 Dec 21 | 2,316 | -66,005 | 23,000 | 25,297 |
| 30 Sep 21 | 2,430 | -43,729 | 15,514 | 22,522 |
| 30 Jun 21 | 2,737 | -55,098 | 17,847 | 24,439 |
| 31 Mar 21 | 3,799 | -57,432 | 21,020 | 35,574 |
| 31 Dec 20 | 4,248 | -65,380 | 19,031 | 37,419 |
| 30 Sep 20 | 4,967 | -159,386 | 20,373 | 40,511 |
| 30 Jun 20 | 5,367 | -153,313 | 19,963 | 37,009 |
| 31 Mar 20 | 4,827 | -114,488 | 16,675 | 26,082 |
| 31 Dec 19 | 4,455 | -106,885 | 17,202 | 21,474 |
| 30 Sep 19 | 3,653 | -29,888 | 23,885 | 10,631 |
| 30 Jun 19 | 3,015 | -26,229 | 21,481 | 9,769 |
| 31 Mar 19 | 3,119 | -41,939 | 17,979 | 7,490 |
| 31 Dec 18 | 3,127 | -27,403 | 14,259 | 6,390 |
| 30 Sep 18 | 3,154 | -13,253 | 10,168 | 5,739 |
| 30 Jun 18 | 3,268 | -8,263 | 6,887 | 4,914 |
| 31 Mar 18 | 3,235 | -7,189 | 5,848 | 4,106 |
| 31 Dec 17 | 3,158 | -6,496 | 5,453 | 3,845 |
| 30 Sep 14 | 5,205 | -2,610 | 4,311 | 478 |
| 30 Jun 14 | 5,484 | -842 | 4,199 | 381 |
| 31 Mar 14 | 5,394 | -90 | 4,056 | 452 |
| 31 Dec 13 | 5,746 | 266 | 3,954 | 438 |
| 30 Sep 13 | 3,956 | -3,107 | 3,775 | 556 |
| 30 Jun 13 | 4,481 | -3,252 | 3,812 | 583 |
Quality Earnings: A084990 is currently unprofitable.
Growing Profit Margin: A084990 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A084990 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.4% per year.
Accelerating Growth: Unable to compare A084990's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A084990 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A084990 has a negative Return on Equity (-39.44%), as it is currently unprofitable.